<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">568946</article-id><article-id pub-id-type="doi">10.26442/00403660.2025.07.203269</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prognostic significance of AIF expression in diffuse large B-cell lymphoma</article-title><trans-title-group xml:lang="ru"><trans-title>Прогностическое значение экспрессии AIF при диффузной В-крупноклеточной лимфоме</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2054-2870</contrib-id><name-alternatives><name xml:lang="en"><surname>Rosin</surname><given-names>Vitaly A.</given-names></name><name xml:lang="ru"><surname>Росин</surname><given-names>Виталий Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, ст. науч. сотр. лаб. патоморфологии</p></bio><email>vaneeva@niigpk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1045-2011</contrib-id><name-alternatives><name xml:lang="en"><surname>Vaneeva</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Ванеева</surname><given-names>Елена Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. биол. наук, науч. сотр. лаб. патоморфологии</p></bio><email>vaneeva@niigpk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8688-1344</contrib-id><name-alternatives><name xml:lang="en"><surname>Diakonov</surname><given-names>Dmitriy A.</given-names></name><name xml:lang="ru"><surname>Дьяконов</surname><given-names>Дмитрий Андреевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, зав. лаб. патоморфологии</p></bio><email>vaneeva@niigpk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-7181-6192</contrib-id><name-alternatives><name xml:lang="en"><surname>Glubokovskikh</surname><given-names>Natalya V.</given-names></name><name xml:lang="ru"><surname>Глубоковских</surname><given-names>Наталья Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>лаборант-исследователь лаб. патоморфологии</p></bio><email>vaneeva@niigpk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8639-719X</contrib-id><name-alternatives><name xml:lang="en"><surname>Samarina</surname><given-names>Svetlana V.</given-names></name><name xml:lang="ru"><surname>Самарина</surname><given-names>Светлана Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, зав. клинико-диагностическим отд. гематологии и химиотерапии с дневным стационаром</p></bio><email>vaneeva@niigpk.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kirov Research Institute of Hematology and Blood Transfusion</institution></aff><aff><institution xml:lang="ru">ФГБУН «Кировский научно-исследовательский институт гематологии и переливания крови» ФМБА</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-07-31" publication-format="electronic"><day>31</day><month>07</month><year>2025</year></pub-date><volume>97</volume><issue>7</issue><issue-title xml:lang="en">Vario (various)</issue-title><issue-title xml:lang="ru">Vario (разное)</issue-title><fpage>545</fpage><lpage>549</lpage><history><date date-type="received" iso-8601-date="2023-08-30"><day>30</day><month>08</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-07-17"><day>17</day><month>07</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/568946">https://ter-arkhiv.ru/0040-3660/article/view/568946</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Dysregulation of apoptosis in diffuse B-large cell lymphoma (DLBCL) contributes to increased tumor proliferation, as well as the formation of resistance to treatment. One of the most relevant areas of molecular research is the study of the mechanisms of programmed cell death – apoptosis. The AIF (Apoptosis Inducing Factor) protein participates in the regulation of the caspase-independent pathway of cell death and is a potential predictor of the course of DLBCL.</p> <p><bold>Aim. </bold>To evaluate the prognostic value of AIF expression in DLBCL.</p> <p><bold>Materials and methods. </bold>A retrospective study included 100 patients with newly diagnosed DLBCL. All patients received standard 1st line therapy according to the R-CHOP scheme. Using histological, immunohistochemical studies of lymph nodes and/or other organs involved in the pathological process were performed. A morphometric calculation of the data was carried out with the determination of the percentage of AIF-expressing tumor cells. The threshold level of expression of these proteins was calculated using by the ROC analysis (57%). Based on the threshold, patients were divided into groups with high (above threshold) and low (subthreshold) protein levels. The calculation of overall (OS) and progression-free (PFS) survival was performed using the Kaplan–Meier method with graphical construction of the corresponding curves, the levels of factors were compared using the log-rank test criterion. The independent influence of factors on the course of DLBCL was determined using multivariate Cox regression analysis.</p> <p><bold>Results. </bold>The subthreshold level of AIF was associated with low rates of OS and PFS of patients (34.9 and 48.8%, respectively). As a result of multivariate Cox analysis, it was found that the AIF protein is an independent prognostic marker for the course of DLBCL.</p> <p><bold>Conclusion. </bold>The subthreshold value of AIF expression is associated with low OS and PFS in patients.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Дисрегуляция апоптоза при диффузной В-крупноклеточной лимфоме (ДВККЛ) способствует усилению пролиферации опухоли, а также формированию резистентности к лечению. Одно из актуальных направлений молекулярных исследований – изучение механизма программируемой гибели клеток – апоптоза. Белок AIF (Apoptosis Inducing Factor) участвует в регуляции каспаз-независимого пути гибели клеток и считается потенциальным предиктором течения ДВККЛ.</p> <p><bold>Цель. </bold>Оценить прогностическое значение экспрессии AIF при ДВККЛ.</p> <p><bold>Материалы и методы. </bold>В ретроспективное исследование включены 100 пациентов с ДВККЛ. Больные получали стандартную терапию 1-й линии по схеме R-CHOP. Выполнены гистологические, иммуногистохимические исследования лимфоузлов и/или других вовлеченных в патологический процесс органов. Проведен морфометрический подсчет данных с определением процентной доли опухолевых клеток, экспрессирующих AIF. С помощью ROC-анализа установлено пороговое значение, равное 57% опухолевых клеток, экспрессирующих AIF. С учетом порога пациентов разделили на группы с высоким (надпороговым) и низким (подпороговым) уровнем белка. Расчет общей (ОВ) и беспрогрессивной выживаемости (БПВ) производили с помощью метода Каплана–Мейера с графическим построением соответствующих кривых, уровни факторов сравнивали с помощью критерия log-rank test. Независимое влияние факторов на течение ДВККЛ определяли с помощью многофакторного анализа регрессии Кокса.</p> <p><bold>Результаты.</bold> Подпороговый уровень AIF связан с низкими показателями ОВ и БПВ пациентов (34,9 и 48,8% соответственно). В результате многофакторного анализа Кокса установлено, что белок AIF – независимый прогностический маркер течения ДВККЛ.</p> <p><bold>Заключение. </bold>Подпороговое значение экспрессии AIF связано с низкой ОВ и БПВ пациентов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>DLBCL</kwd><kwd>diffuse large B-cell lymphoma</kwd><kwd>AIF</kwd><kwd>overall survival</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ДВККЛ</kwd><kwd>диффузная В-крупноклеточная лимфома</kwd><kwd>AIF</kwd><kwd>общая выживаемость</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. IARC: Lyon, 2017.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Wang L, Li L, Young K, et al. New agents and regimens for difuse large B cell lymphoma. J Hematol Oncol. 2020;13:175. DOI:10.1186/s13045-020-01011-z</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Капланов К.Д., Волков Н.П., Клиточенко Т.Ю., и др. Результаты анализа регионального регистра пациентов с диффузной В-крупноклеточной лимфомой: факторы риска и проблемы иммунохимиотерапии. Клиническая онкогематология. 2019;12(2):154-64 [Kaplanov KD, Volkov NP, Klitochenko TYu, et al. Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemommunotherapy Issues. Klinicheskaya Onkogematologiya. 2019;12(2):154-64 (in Russian)]. DOI:10.21320/2500-2139-2019-12-2-154-164</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Шардаков В.И., Сухорукова Э.Е. Биологическое и клиническое значение проявлений апоптоза у людей. Киров, 2019. С. 5-78 [Shardakov VI, Sukhorukova EE. Biological and clinical significance of apoptosis manifestations in humans. Kirov, 2019. P. 5-78 (in Russian)].</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Sevrioukova I. Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid Redox Signal. 2011;14(12):2545-79. DOI:10.1089/ars.2010.3445</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Фадеева Н.П., Антипова Н.В., Шендер В.О., и др. Определение белков наружной мембраны митохондрий, взаимодействующих с белком AIF. Asta Naturae. 2018;10(4):100-9 [Fadeeva NP, Antipova NV, Shender VO, et al. Identification of mitochondrial outer membrane proteins interacting with AIF protein. Asta Naturae. 2018;10(4):100-9 (in Russian)]. DOI:10.32607/20758251-2018-10-4-100-109</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Дятлова А.С., Дудков А.В., Линькова Н.С., и др. Молекулярные маркеры каспазо-зависимого и митохондриального апоптоза: роль в развитии патологии и в процессе клеточного старения. Успехи современной биологии. 2018;138(2):126-37 [Dyatlova AS, Dudkov AV, Linkova NS, et al. Molecular markers of caspase-dependent and mitochondrial apoptosis: role in the development of pathology and in the process of cell aging. Advances in Modern Biology. 2018;138(2):126-37 (in Russian)]. DOI:10.7868/S0042132418020023</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Banoa D, Prehn J. Apoptosis-Inducing Factor (AIF) in Physiology and Disease: The Tale of a Repented Natural Born Killer. EBio Medicine. 2018;30:29-37. DOI:10.1016/j.ebiom.2018.03.016</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Letkovska K, Babal P, Cierna Z, et al. Prognostic Value of Apoptosis-Inducing Factor (AIF) in Germ Cell Tumors. Cancers. 2021;13(4):776. DOI:10.3390/cancers13040776</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Xing Y, Li Y, Hu B, et al. PAK5-mediated AIF phosphorylation inhibits its nuclear translocation and promotes breast cancer tumorigenesis. Int J Biol Sci. 2021;17(5):1315-27. DOI:10.7150/ijbs.58102</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Perraud A, Akil H, Nouaille M, et al. Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: correlation with advanced stages. Oncol Rep. 2011;26:1091-7. DOI:10.3892/or.2011.1404</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Cabon L, Bertaux A, Brunelle-Navas M, et al. AIF loss deregulates hematopoiesis and reveals different adaptive metabolic responses in bone marrow cells and thymocytes. Cell Death Differ. 2018;25:983-1001. DOI:10.1038/s41418-017-0035-x</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Delavallée L, Mathiah N, Cabon L, et al. Mitochondrial AIF loss causes metabolic reprogramming, caspase-independent cell death blockade, embryonic lethality, and perinatal hydrocephalus. Mol Metab. 2020;40:101027. DOI:10.1016/j.molmet.2020.101027</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Troutaud D, Petit B, Bellanger C, et al. Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(2):118-24. DOI:10.3816/CLML.2010.n.016</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Cardama A, Qiu Yi H, Post S, et al. Phase Protein Array Profiling Reveals Distinct Proteomic Signatures Associated With Chronic Myeloid Leukemia Progression and With Chronic Phase in the CD34-Positive Compartment. Cancer. 2012;118(21):5283-92. DOI:10.1002/cncr.27568</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ванеева Е.В., Росин В.А., Дьяконов Д.А., и др. Оценка прогностического значения экспрессии pSTAT3 при диффузной В-крупноклеточной лимфоме на российской выборке пациентов. Сибирский научный медицинский журнал. 2019;39(5):125-33 [Vaneeva EV, Rosin VA, Dyakonov DA, et al. Evaluation of the prognostic value of pSTAT3 expression in diffuse B-large cell lymphoma in a Russian sample of patients. Siberian Scientific Medical Journal. 2019;39(5):125-33 (in Russian)]. DOI:10.20538/1682-0363-2021-3-13-20</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ванеева Е.В., Росин В.А., Дьяконов Д.А., и др. Значение экспрессии рАКТ1 при диффузной В-крупноклеточной лимфоме. Бюллетень сибирской медицины. 2021;3:6-13 [Vaneeva EV, Rosin VA, Dyakonov DA, et al. Significance of pAKT1 expression in diffuse large B-cell lymphoma. Bulletin of Siberian Medicine. 2021;3:6-13 (in Russian)]. DOI:10.20538/1682-0363-2021-3-13-20</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Artus C, Boujrad H, Bouharrour A, et al. AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX. EMBO J. 2010;29(9):1585-99. DOI:10.1038/emboj.2010.43</mixed-citation></ref></ref-list></back></article>
